These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 30498492)

  • 1. Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies.
    Lancman G; Arinsburg S; Jhang J; Cho HJ; Jagannath S; Madduri D; Parekh S; Richter J; Chari A
    Front Immunol; 2018; 9():2616. PubMed ID: 30498492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
    Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
    Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: Effects of anti-CD38 monoclonal antibodies on red blood cell transfusion and interventions.
    Song J; Fu R
    J Clin Lab Anal; 2021 Dec; 35(12):e23832. PubMed ID: 34752645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing.
    De Vooght KM; Oostendorp M; van Solinge WW
    Curr Opin Hematol; 2016 Nov; 23(6):557-562. PubMed ID: 27389485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab: Therapeutic asset, biological trap!
    Deneys V; Thiry C; Frelik A; Debry C; Martin B; Doyen C
    Transfus Clin Biol; 2018 Feb; 25(1):2-7. PubMed ID: 29336950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
    van de Donk NW; Moreau P; Plesner T; Palumbo A; Gay F; Laubach JP; Malavasi F; Avet-Loiseau H; Mateos MV; Sonneveld P; Lokhorst HM; Richardson PG
    Blood; 2016 Feb; 127(6):681-95. PubMed ID: 26631114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform?
    Habicht CP; Ridders M; Grueger D; Adolph S; Immenschuh S; Schneeweiss C
    Transfusion; 2023 Apr; 63(4):808-816. PubMed ID: 36707937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy.
    Anani WQ; Marchan MG; Bensing KM; Schanen M; Piefer C; Gottschall JL; Denomme GA
    Transfusion; 2017 Jun; 57(6):1470-1479. PubMed ID: 28150308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.
    Oostendorp M; Lammerts van Bueren JJ; Doshi P; Khan I; Ahmadi T; Parren PW; van Solinge WW; De Vooght KM
    Transfusion; 2015 Jun; 55(6 Pt 2):1555-62. PubMed ID: 25988285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.
    Chami B; Okuda M; Moayeri M; Pirenne F; Hidaka Y; Nambiar A; Song Z; Bedel O; Zhang B; Hopke J; Deng G; Zhu C; Macé S; Chiron M; Adrian F; Fukao T; Basile FG; Martin T
    Transfusion; 2022 Nov; 62(11):2334-2348. PubMed ID: 36239134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.
    Chari A; Arinsburg S; Jagannath S; Satta T; Treadwell I; Catamero D; Morgan G; Feng H; Uhlar C; Khan I; Doshi P; Usmani S
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):44-51. PubMed ID: 29054515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How do transfusion services manage patients taking therapies such as anti-CD38 and anti-CD47 known to interfere with red blood cell compatibility testing?
    Murphy MF; Rajbhandary S; Carayiannis S; Cohn CS
    Transfusion; 2024 Jul; 64(7):1217-1222. PubMed ID: 38767410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How do I work up pretransfusion samples containing anti-CD38?
    Anani WQ; Duffer K; Kaufman RM; Denomme GA
    Transfusion; 2017 Jun; 57(6):1337-1342. PubMed ID: 28474469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
    Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
    Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-based therapies.
    Carreño-Tarragona G; Cedena T; Montejano L; Alonso R; Miras F; Valeri A; Rivero A; Lahuerta JJ; Martinez-Lopez J
    Transfus Med; 2019 Jun; 29(3):193-196. PubMed ID: 29369430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of new myeloma agents on the transfusion laboratory.
    Jones AD; Moayeri M; Nambiar A
    Pathology; 2021 Apr; 53(3):427-437. PubMed ID: 33707006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.
    Zannetti BA; Faini AC; Massari E; Geuna M; Maffini E; Poletti G; Cerchione C; Martinelli G; Malavasi F; Lanza F
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.
    Phou S; Costello C; Kopko PM; Allen ES
    Transfusion; 2021 Jul; 61(7):2054-2063. PubMed ID: 33960433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daratumumab in multiple myeloma.
    Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
    Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.